Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:Daunorubicin formulation, in consolidation treatment against human leukemia xenografts

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1536-1542

  Lim, Wah Seng ^a   Tardi, Paul G ^a   Xie, Xiaowei ^a   Fan, Mannie ^a   Huang, Ruby ^a   Ciofani, Travis ^a   Harasym, Troy O ^a   Mayer, Lawrence D ^a  

^a Celator Pharmaceuticals Corp   (Canada)

Author keywords

acute leukemia; Consolidation treatment; drug delivery; efficacy; pharmacodynamics

Indexed keywords

ANTILEUKEMIC AGENT; CPX 351; CYTARABINE; DAUNORUBICIN; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; T CELL LEUKEMIA; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CHEMISTRY, PHARMACEUTICAL; CYTARABINE; DAUNORUBICIN; DNA-BINDING PROTEINS; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; LIPOSOMES; MAXIMUM TOLERATED DOSE; MICE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955441915     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.490312     Document Type: Article

References (11)

1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
2. McCauley DL. Treatment of adult acute leukemia. Clin Pharm 1992;11:767-796.
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163.
4. Lancet J, Feldman E, Cortes J, et al. Phase IIb randomized study of CPX-351 vs. conventional cytarabine+daunorubicin in newly diagnosed AML patients aged 60-75: safety report. Blood 2009;114(Suppl. 1):427 (Abstract 1033).
5. Harasym TO, Liboiron BD, Mayer LD. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol Biol 2010;596:291-323.
6. Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5:1854-1863.
7. Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009;33:129-139.
8. Feldman EJ, Lancet J, Kolitz JE, et al. Phase I study of a liposomal carrier (CPX-351) containing a synergistic, fixed molar ratio of cytarabine (Ara-C) and daunorubicin (DNR) in advanced leukemias. Blood 2008;112(Suppl. 1):1025 (Abstract 2984).
9. Lim W-S, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 2010 Feb 5. [Epub ahead of print].
10. Kapinsky M, Torzewski M, Buchler C, Duong CQ, Rothe G, Schmitz G. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavengerreceptor CD36. Arterioscler Thromb Vasc Biol 2001;21: 1004-1010.
11. Tait JF, Smith C. Phosphatidylserine receptors: role of CD36 in binding of anionic phospholipid vesicles to monocytic cells. J Biol Chem 1999;274:3048-3054.